Advertisement

Myeloma Remission Is Produced by Re-Engineered Measles Virus in Early Studies — Physician’s First Watch

Medical News |
May 19, 2014

Myeloma Remission Is Produced by Re-Engineered Measles Virus in Early Studies

By Joe Elia

Two patients with disseminated, treatment-resistant multiple myeloma have shown promising responses to therapy with a re-engineered measles virus, according to a Mayo Clinic Proceedings study that's gotten a lot of press attention.

The patients both received large doses of a measles virus strain used to make vaccine. The virus was further changed to let researchers track its entry into myeloma cells, which carry a receptor to which the virus readily attaches. Infection causes the destruction of the target cells. One patient had a forehead lesion that shrank dramatically; she had a complete remission of all metastases lasting 9 months. The other patient showed improvement in only some lesions.

An editorialist writes that the work provides "compelling evidence that a single infusion of an [oncolytic virus] can lead to complete systemic antitumor responses, even in patients with advanced cancer." The lead researcher is similarly enthusiastic in a video presentation.

Reader Comments (3)

Giuseppe Finzi Physician, Internal Medicine, University Hospital of Parma, Italy

A promising challenge, both for incoming therapies and for knowledge of tumor(s) biology

L. Vestin Physician, Hematology

The Journal Watch gives a good, very good concentrated information.

Newton Hokama Physician, Hematology, universidade estadual paulista

very interesting

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement